Press "Enter" to skip to content

India’s First ‘Tata CRISPR’ Covid-19 Test Gets Approval by DCGI for Commercial Launch

Image just for illustration. (AP Photo)

The Tata CRISPR take a look at is the world’s first diagnostic take a look at to deploy a specifically tailored Cas9 protein to efficiently detect the virus inflicting Covid-19.

  • IANS
  • Last Updated: September 19, 2020, 10:55 PM IST

  • FOLLOW US ON:

The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) take a look at, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology), acquired regulatory approval on Saturday from the Drug Controller General of India for its business launch, assembly high-quality benchmark with 96 per cent sensitivity and 98 per cent specificity for detecting novel coronavirus.

The take a look at makes use of an indigenously developed, cutting-edge CRISPR expertise for detection of the genomic sequence of the SARS-CoV-2 virus. CRISPR is a genome enhancing expertise for diagnosing ailments.






The Tata CRISPR take a look at is the world’s first diagnostic take a look at to deploy a specifically tailored Cas9 protein to efficiently detect the virus inflicting Covid-19.

This marks a major achievement for the Indian scientific group, shifting from R&D to a high-accuracy, scalable and dependable take a look at in lower than 100 days.

The Tata CRISPR take a look at achieves accuracy ranges of conventional RT-PCR checks, with faster turnaround time, inexpensive tools, and higher ease of use. Moreover, CRISPR is a futuristic expertise that will also be configured for the detection of a number of different pathogens sooner or later.

The effort is the results of a fruitful collaboration between the scientific group and the trade. The Tata Group has labored intently with CSIR-IGIB and ICMR to create a high-quality take a look at that may assist the nation ramp up Covid-19 testing shortly and economically, with a made in India product that’s secure, dependable, reasonably priced and accessible.

Commenting on the event, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd, mentioned, “The approval for the Tata CRISPR test for Covid-19 will give a boost to the country’s efforts in fighting the pandemic. The commercialisation of the Tata CRISPR test reflects the tremendous R&D talent in the country, which can collaborate to transform India’s contributions to the global healthcare and scientific research world.”

Shekhar C. Mande, DG, CSIR, complimented the CSIR-IGIB staff of scientists and college students, TATA Sons and DCGI for the exemplary work and collaboration carried out throughout the present pandemic, resulting in the approval of the novel diagnostic equipment and paving the trail for additional improvements in the direction of making India self-reliant.

Anurag Agrawal, Director, CSIR-IGIB, expressed delight that the work began by CSIR underneath the sickle cell mission for genome diagnostics and therapeutics led to new information that may very well be harnessed to shortly develop new diagnostic take a look at for SARS-CoV-2.

He emphasised that this reveals the interconnectedness of scientific information and expertise and the innovation of the younger analysis staff led by Debojyoti Chakraborty and Souvik Maiti.


Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    %d bloggers like this: